IP Library Granted Patent US 9,062,130
Granted Patent B2
US 9,062,130 · App. 14/024,916 · Granted Jun 23, 2015

Cross-linking of low-molecular weight and high-molecular weight polysaccharides, preparation of injectable monophase hydrogels, polysaccharides and hydrogels obtained

Inventor: Pierre F. Lebreton (Annecy, FR)
Assignee: Allergan Industrie SAS
C08B37/0072A61L27/20A61L27/50A61L27/52C08J3/24C08J2305/08C08L5/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,062,130
App. No.
14/024,916
Granted
Jun 23, 2015
Kind
B2
Abstract

A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes.

Claims (12)

1. An injectable hydrogel useful as a filling material in plastic surgery, the hydrogel made by a process comprising the steps of:

1) forming a mixture of a first hyaluronic acid salt product having a first molecular weight and a second hyaluronic acid salt product having a second molecular weight greater than the first molecular weight, wherein the first hyaluronic acid salt product and the second hyaluronic acid salt product are two separate pre-existing products prior to the forming step, wherein the mixture contains about 90% by weight of the first hyaluronic acid salt product and about 10% by weight of the second hyaluronic acid salt product, wherein the first hyaluronic acid salt product is a sodium salt having a molecular weight of about 3×10 5 Da, and the second hyaluronic acid salt product is a sodium salt having a molecular weight of about 3×10 6 Da;

2) cross-linking the mixture of step 1) in an aqueous solvent in the presence of an effective and non-excessive amount of at least one cross-linking agent, such that the degree of cross-linking, defined by the ratio: 100×(total number of reactive groups in said cross-linking agent/total number of disaccharide units in the first hyaluronic acid salt and second hyaluronic acid salt), is theoretically between 0.5 and 70%; and

3) formulating the cross-linked mixture of step 2), into a solution buffered to a pH of between 6.5 and 7.5.

2. The hydrogel according to claim 1 , wherein said mixture has an intrinsic viscosity of less than 1900 ml/g.

3. The hydrogel according of claim 1 , wherein said cross-linking agent is selected from bifunctional crosslinking agents and mixtures thereof.

4. The hydrogel according to claim 1 , wherein the degree of cross-linking is theoretically between 4 and 50%.

5. The hydrogel according to claim 1 , wherein said cross-linking agent is selected from epichlorohydrin, divinyl sulfone, 1,4-bis(2,3-epoxypropoxy)butane, 1,2-bis(2,3-epoxypropoxy)ethylene, 1-(2,3-epoxypropyl)-2,3-epoxycyclohexane, aldehydes, and mixtures thereof.

6. The hydrogel according to claim 5 , wherein said aldehydes are selected from formaldehyde, glutaraldehyde, crotonaldehyde, and mixtures thereof.

7. The hydrogel according to claim 1 , wherein said cross-linking agent is 1,4-bis(2,3-epoxypropoxy)butane.

8. The hydrogel according to claim 1 , wherein the pH is between 7 and 7.4.

9. The hydrogel according to claim 1 , wherein the pH is between 7.1 and 7.3.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 10, 2015
From: LEBRETON, PIERRE
To: CORNEAL INDUSTRIE
Reel/Frame 034928/0655 →
CHANGE OF NAME Recorded Feb 10, 2015
From: CORNEAL INDUSTRIE
To: ALLERGAN INDUSTRIES SAS
Reel/Frame 034934/0672 →
Priority Claims (1)
FR 03 04444 · Apr 10, 2003 · national
Continuity (4)
Continuation 13566767 · Aug 3, 2012
Continuation 12782488 · May 18, 2010
Division 10552309
Related Publication 20140011990A1 · Jan 9, 2014